EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab

Yufan Zhou iD, Rongjing Guo, Xingyu Xia, Sisi Jing, Jun Lu, Zhe Ruan, Sushan Luo iD, Xiao Huan, Chongbo Zhao iD, Ting Chang iD, Jianying Xi

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Yufan Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rituximab, Myasthenia Gravis, Nomograms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project, ZJLab, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to establish and validate a predictive nomogram for the short‐term clinical outcomes of myasthenia gravis (MG) patients treated with low‐dose rituximab.

Methods

We retrospectively reviewed 108 patients who received rituximab of 600 mg every 6 months in Huashan Hospital and Tangdu Hospital. Of them, 76 patients from Huashan Hospital were included in the derivation cohort to develop the predictive nomogram, which was externally validated using 32 patients from Tangdu Hospital. The clinical response is defined as a ≥ 3 points decrease in QMG score within 6 months. Both clinical and genetic characteristics were included to screen predictors via multivariate logistic regression. Discrimination and calibration were measured by the area under the receiver operating characteristic curve (AUC‐ROC) and Hosmer–Lemeshow test, respectively.

Results

Disease duration (OR = 0.987, p = 0.032), positive anti‐muscle‐specific tyrosine kinase antibodies (OR = 19.8, p = 0.007), and genotypes in FCGR2A rs1801274 (AG: OR = 0.131, p = 0.024;GG:OR = 0.037, p = 0.010) were independently associated with clinical response of post‐rituximab patients. The nomogram identified MG patients with clinical response with an AUC‐ROC (95% CI) of 0.875 (0.798–0.952) in the derivation cohort and 0.741(0.501–0.982) in the validation cohort. Hosmer–Lemeshow test showed a good calibration (derivation: Chi‐square = 3.181, p = 0.923; validation: Chi‐square = 8.098, p = 0.424).

Conclusions

The nomogram achieved an optimal prediction of short‐term outcomes in patients treated with low‐dose rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMyasthenia GravisNomogramsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesImmunologic FactorsTreatment OutcomeAgedYoung AdultReceptors, IgG

Stichwörter der Autor:innen

myasthenia gravisnomogrampredictorprognosisrituximab

Substanzen

RituximabImmunologic FactorsReceptors, IgG

Autor:innen und Institutionen

  • Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
  • Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China.
  • National Center for Neurological Diseases, Shanghai, China.
  • Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
  • Department of Neurology, Banan Hospital, Chongqing Medical University, Chongqing, China.

ORCID-Profile: Yufan Zhou, Sushan Luo, Chongbo Zhao, Ting Chang

Förderung

  • Shanghai Municipal Science and Technology Major Project
  • ZJLab
  • National Natural Science Foundation of China
  • National Key Research and Development Plan of China

Zitieren

APA

Zhou, Y., Guo, R., Xia, X., Jing, S., Lu, J., Ruan, Z., Luo, S., Huan, X., Zhao, C., Chang, T., & Xi, J. (2024). A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14761

Vancouver

Zhou Y, Guo R, Xia X, Jing S, Lu J, Ruan Z, et al. A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14761

BibTeX
@article{Zhou2024,
  author = {Zhou, Yufan and Guo, Rongjing and Xia, Xingyu and Jing, Sisi and Lu, Jun and Ruan, Zhe and Luo, Sushan and Huan, Xiao and Zhao, Chongbo and Chang, Ting and Xi, Jianying},
  title = {A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14761}
}
Kostenlos starten →